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PD-L1 expression and its
clinicopathological correlation in advanced
esophageal squamous cell carcinoma in a
Chinese population
Lulu Rong1, Yong Liu2, Zhouguang Hui3, Zitong Zhao4, Yueming Zhang2, Bingzhi Wang1, Yanling Yuan1,
Wenbin Li1, Lei Guo1, Jianming Ying1, Yongmei Song4, Luhua Wang3, Zhongren Zhou5, Liyan Xue1,6* and
Ning Lu1*

Abstract
Background: Programmed death ligand 1 (PD-L1) is a ligand for the inhibitory programmed cell death protein 1 (PD1), which are targeted by several anti-PD-1 and PD-L1 drugs for a variety of human cancers. However, only a few
studies have evaluated PD-L1 expression in esophageal squamous cell carcinoma (ESCC) with a large Chinese cohort.
Our present study is to evaluate the association of PD-L1 expression with clinicopathological features on ESCC.
Methods: Using tissue microarray and immunohistochemistry, PD-L1 expression on tumor cells and tumor-infiltrating
immune cells was studied in 378 advanced ESCC patients without neoadjuvant chemoradiotherapy. Its correlation with
clinicopathological parameters was analyzed.
Results: PD-L1 was expressed on 29.9% (113/378) ESCC tumor cells and 40.2% (152/378) tumor-infiltrating immune
cells. PD-L1 expression in tumor cells was significantly correlated with age, degree of differentiation, T stage, N stage
and metachronous hematogenous metastasis, and PD-L1 expression in tumor-infiltrating immune cells was significantly
associated with N stage (P < 0.05). Patients with PD-L1 expression in tumor cells had poor disease-free survival (Hazard
ratio [HR] = 1.436, P = 0.009). There was a positive association between tumor cells and tumor-infiltrating immune cells for
PD-L1 expression (r = 0.16, P = 0.002). However, PD-L1 expression in tumor-infiltrating immune cells was not significantly
correlated with disease-free survival and overall survival.
Conclusions: PD-L1 expression in tumor cells and tumor infiltrating immune cells is not only an indicator for
immunotherapy, but also significantly related with age, differentiation, stage, metastasis and disease free survival.
Keywords: PD-L1, Esophageal squamous cell carcinoma, Clinicopathological parameters, Disease-free survival, Recurrence

Background
Esophageal squamous cell carcinoma (ESCC) is the 3rd
most common cause of death from cancer in China [1].
In spite of great progress of surgery and other treatments, the prognosis of patients with advanced ESCC is
still very poor [2]. New therapies are urgently needed to
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improve the survival rate and survival quality for advanced ESCC.
The immune checkpoint programmed cell death protein 1 (PD-1) is expressed in tumor-infiltrating immune
cells including T-lymphocytes, B-lymphocytes, natural
killer cells, monocytes, and dendritic cells. It is engaged
by the tumor expressed ligands including programmed
death ligand 1 (PD-L1) and PD-L2, which increases the
apoptosis of activated tumor-reactive T-cells and promotes the growth of tumor cells in vivo [3]. Recently,
PD-L1 immune checkpoint inhibitor antibodies in multiple clinical trials were used to treat many cancer types
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[4–9], including melanoma, non-small cell lung cancer
(NSCLC), hepatocellular carcinoma, esophageal cancer
and bladder cancer.
In recent years, the relationship between PD-L1 expression and clinical outcomes have been studied in ESCC
[10–16]. However, the association of PD-L1 expression
with the clinicopathological relationship in ESCC remains
controversial. Some studies demonstrated that PD-L1 expression was correlated with poor prognosis [10, 17],
while some studies suggested that PD-L1 could be a favorable prognostic indicator in ESCC [12]. In one study,
PD-L1 expression was found to be not related to prognosis [18]. Our study aims to study the expression of PD-L1
in T2-T4a ESCC in a Chinese population and analyze its
correlation with clinicopathological parameters and prognosis. These might provide a clue of the potential immune
based therapy strategy for ESCC patients.

Methods
Tissue samples

A total of 378 patients with primary esophageal squamous cell carcinoma, who received radical esophagectomy without neoadjuvant chemoradiotherapy in
National Cancer Center/National Clinical Research Center for Cancer/Chinese Academy of Medical Sciences
and Peking Union Medical College between April 1999
and March 2003, were included in this retrospective
study. This study contained T2 stage (n = 103), T3 stage
(n = 238), T4a stage (n = 37), N1 stage (n = 116), N2 stage
(n = 52), and N3 stage (n = 21) cases. These cases were
non-consecutive cases which had complete follow-up
data. The patients’ medical records were reviewed to obtain patients’ clinicopathological parameters, including
age at diagnosis, gender, tumor differentiation, tumor location, vascular invasion, perineural invasion, metachronous hematogenous metastasis, and pathological TNM
stage (Table 2). The HE slides were reviewed by two pathologists (Lulu Rong and Liyan Xue) to obtain pathological parameters, and any arguments were resolved by
consensus review. TNM staging according to the 8th
American Joint Committee on Cancer (AJCC) TNM
classification [19].
Tissue microarray construction

All tumor samples were fixed in 10% neutral buffered formalin for 12–48 h and embedded in paraffin. Tissue microarrays (TMAs) were constructed from three 0.6-mm
cores of tumor tissue and three 0.6-mm cores of normal
epithelium from each case using a Manual Tissue Arrayer
(MTA-1, Beecher Instruments, Silver Spring, MD).
Immunohistochemistry (IHC)

The IHC Envision staining method was used for immunohistochemical staining. Antigen retrieval was performed
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by pressure oven 2.5 min in EDTA (pH 9.0). Slides
were incubated for 15 min with H2O2 (Dako,
Glostrup, Denmark). The primary antibody, rabbit
anti-PD-L1 monoclonal antibody (clone SP142; 1:50,
Spring Bioscience, Pleasanton, CA, USA) was incubated sequentially for two hours at room temperature.
The bound antibody was then detected with the
horseradish peroxidase (HRP)-labeled goat antimouse/rabbit secondary antibody (Dako, Glostrup,
Denmark) for 30 min at room temperature. Finally,
reaction products were visualized with 3, 3′-diaminobenzidine (DAB, Dako, Glostrup, Denmark). Slides
were lightly counterstained with hematoxylin.
Evaluation of IHC

In our study, tumor cells and tumor-infiltrating immune
cells were quantified by evaluating the percentage of
stained and unstained cells (number of PD-L1-positive
tumor cells/number of all tumor cells or number of
PD-L1-positive tumor-infiltrating immune cells/number
of all tumor-infiltrating immune cells). The proportion
of PD-L1 positive expression in tumor cells was estimated as different thresholds (< 1%, 1–9%, 10–49%, or ≥
50%) (Table 1), Tumor cells were designated PD-L1 positive expression when ≥1% of the tumor cells were positive for PD-L1, evaluated as partially or completely
staining on the cell membrane or cell membrane and
cytoplasm for tumor cells. Positive PD-L1 expression on
immune cells was defined as ≥1% positive cells with
membranous or cytoplasmic staining. Necrotic areas
were excluded from scoring. IHC results were evaluated
by two pathologists (Lulu Rong and Liyan Xue) in a
blinded manner. Doubtful cases were discussed by the
two pathologists using a multiheaded microscope until
consensus was achieved.
Statistical analysis

SPSS 19.0 software was used for statistical analysis. The
significance of the difference between PD-L1 expression
and clinicopathological parameters was assessed by the
univariate Logistic regression analysis. The relationship
between tumor cells and tumor-infiltrating immune cells
for PD-L1 expression was examined using correlation
analysis. Disease-free survival rates and overall survival
rates were calculated and survival curves were constructed using the Kaplan-Meier method, and the
log-rank test was used to evaluate the statistical
Table 1 PD-L1 expression based on the percent-positive tumor
cells by immunohistochemical staining
PD-L1 expression
in tumor cells (%)

< 1%

1–9%

10–49%

≥50%

Overall

265(70.1%)

51(13.5%)

34(9.0%)

28(7.4%)
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significance of differences. The prognostic significance
of clinicopathological parameters was determined using
univariate Cox proportional hazards analysis. To assess
the presence of possible confounding variables, the backward stepwise multivariate Cox proportional hazards
analysis was applied for factors that achieved significance
in univariate Cox proportional hazards analysis. Hazard
ratios (HR) with 95% confidence intervals (CIs) were
reported.
All statistical tests were conducted as two-sided, and
P < 0.05 was considered to indicate a statistically significant difference.

Results
PD-L1 expression in ESCC tumor cells and its correlation
with clinicopathological parameters

PD-L1 was found to be located on the cell membrane
and/or cytoplasm in ESCC tumor cells and tumor-infiltrating immune cells (Fig. 1). The expression of PD-L1 in
ESCC tumor cells was positive in 29.9% (113/378), which
was associated with various clinicopathological
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parameters including age, degree of differentiation, T
stage, N stage and metachronous hematogenous metastasis. Poor differentiation ESCC had higher PD-L1
positive expression (Table 2).
PD-L1 expression in ESCC tumor-infiltrating immune cells
and its correlation with clinicopathological parameters

PD-L1 positive expression in ESCC tumor-infiltrating
immune cells was 40.2% (152/378) (Table 3). PD-L1
expression in tumor-infiltrating immune cells was significantly associated with N stage (P < 0.05) (Table 3).
PD-L1 expression in tumor-infiltrating immune cells
was significantly associated with PD-L1 expression in
tumor cells (r = 0.16, P = 0.002; Table 4, Fig. 2).
Correlation between PD-L1 expression in ESCC tumor
cells and prognosis

The median disease-free survival time (DFS) was 41
months in PD-L1 negative patients and 18 months in
PD-L1 positive patients, respectively. PD-L1 expression
was significantly associated with shorter DFS (P = 0.008).

Fig. 1 PD-L1 expression in esophageal squamous cell carcinoma (ESCC) and adjacent non-malignant epithelium by immunohistochemistry staining.
a Strong positive expression of PD-L1 in tumor cells. Original magnification, 400×. b Weak positive expression of PD-L1 in tumor cells. Original
magnification, 400×. c Negative expression of PD-L1 in tumor cells. Original magnification, 400×. d The adjacent non-malignant epithelium. Original
magnification, 200×. e Positive expression of PD-L1 in tumor-infiltrating immune cells. Original magnification, 400×. f Negative expression of PD-L1 in
tumor-infiltrating immune cells. Original magnification, 400 ×
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Table 2 Relationships between clinicopathological characteristics and PD-L1 expression in tumor cells
Clinicopathological characteristics

Overall

PD-L1 (+)

PD-L1 (−)

378

113(29.9%)

265(70.1%)

Age at diagnosis

Odds ratio (95% CI)

Global P

1.563(1.003–2.438)

0.049

0.800(0.461–1.386)

0.425

≥ 60 years

188

65(34.6%)

123(65.4%)

< 60 years

190

48(25.3%)

142(74.7%)

Male

307

89(29.0%)

218(71.0%)

Female

71

24(33.8%)

47(66.2%)

Well

85

21(24.7%)

64(75.3%)

1

Moderate

190

51(26.8%)

139(73.2%)

1.118(0.621–2.013)

0.710

Poor

91

38(41.8%)

53(58.2%)

2.185(1.146–4.166)

0.018

Basaloid

12

3(25.0%)

9(75.0%)

1.016(0.251–4.105)

0.982

Upper thoracic

61

18(29.5%)

43(70.5%)

1

Middle thoracic

209

59(28.2%)

150(71.8%)

0.940(0.502–1.759)

0.846

Lower thoracic

108

36(33.3%)

72(66.7%)

1.194(0.605–2.358)

0.609

1.821(1.068–3.106)

0.028

pT2

103

22(21.4%)

81(78.6%)

pT3-4a

275

91(33.1%)

184(66.9%)
1.541(1.210–1.963)

< 0.001

1.025(0.656–1.600)

0.915

0.823(0.512–1.324)

0.422

2.030(1.171–3.520)

0.012

Gender

Tumor differentiation

Location

PT status

PN status
pN0

189

40(21.2%)

149(78.8%)

pN1

116

43(37.1%)

73(62.9%)

pN2

52

20(38.5%)

32(61.5%)

pN3

21

10(47.6%)

11(52.4%)

No

219

65(29.7%)

154(70.3%)

Yes

159

48(30.2%)

111(69.8%)

Vascular invasion

Perineural invasion
No

253

79(31.2%)

174(68.8%)

Yes

125

34(27.2%)

91(72.8%)

Metachronous
hematogenous metastasis
No

313

85(27.2%)

228(72.8%)

Yes

65

28(43.1%)

37(56.9%)

The median overall survival time (OS) was 60 months
in PD-L1 negative patients and 36 months in PD-L1
positive patients, respectively. PD-L1 expression patients had a shorter OS, but not statistically significant (P = 0.140) (Fig. 3). Univariate Cox analysis
showed that patients with PD-L1 expression had poor
DFS (Hazard ratio [HR] = 1.436, 95% CI: 1.095–1.883,
P = 0.009) (Table 5). However, multivariate Cox analysis failed to show PD-L1 as an independent prognostic factor (Table 6).

Correlation between PD-L1 expression in ESCC tumorinfiltrating immune cells and prognosis

The median DFS was 36 months in PD-L1 positive
tumor-infiltrating immune cells patients and 34 months
in PD-L1 negative patients, respectively. The median OS
was 53 months in PD-L1 positive tumor-infiltrating immune cells patients and 47 months in PD-L1 negative
patients, respectively. No statistical significance was
found in both DFS and OS between PD-L1 positive and
negative tumor-infiltrating immune cell patients (median
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Table 3 Relationships between clinicopathological characteristics and PD-L1 expression in tumor-infiltrating immune cells
Clinicopathological characteristics

Overall

PD-L1 (+)

PD-L1 (−)

378

152(40.2%)

226(59.8%)

≥ 60 years

188

72(38.3%)

116(61.7%)

< 60 years

190

80(42.1%)

110(57.9%)

Odds ratio (95% CI)

Age at diagnosis

Gender
Male

307

126(41.0%)

181(59.0%)

Female

71

26(36.6%)

45(63.4%)

85

32(37.6%)

53(62.4%)

Global P

0.853(0.565–1.288)

0.450

1.205(0.707–2.055)

0.494

Tumor differentiation
Well

1

Moderate

190

77(40.5%)

113(59.5%)

1.129(0.667–1.909)

0.652

Poor

91

37(40.7%)

54(59.3%)

1.135(0.619–2.081)

0.683

Basaloid

12

6(50.0%)

6(50.0%)

1.656(0.492–5.575)

0.415

Location
Upper thoracic

61

24(39.3%)

37(60.7%)

1

Middle thoracic

209

71(34.0%)

138(66.0%)

0.793(0.441–1.428)

0.440

Lower thoracic

108

57(52.8%)

51(47.2%)

1.723(0.911–3.260)

0.094

1.211(0.760–1.931)

0.421

1.630(1.286–2.067)

< 0.001

0.729(0.479–1.110)

0.141

0.939(0.606–1.455)

0.778

0.989(0.574–1.707)

0.969

PT status
pT2

103

38(36.9%)

65(63.1%)

pT3-4a

275

114(41.5%)

161(58.5%)

189

53(28.0%)

136(72.0%)

PN status
pN0
pN1

116

61(52.6%)

55(47.4%)

pN2

52

26(50.0%)

26(50.0%)

pN3

21

12(57.1%)

9(42.9%)

Vascular invasion
No

219

95(43.4%)

124(56.6%)

Yes

159

57(35.8%)

102(64.2%)

No

253

103(40.7%)

150(59.3%)

Yes

125

49(39.2%)

76(60.8%)

Perineural invasion

Metachronous hematogenous
metastasis
No

313

126(40.3%)

187(59.7%)

Yes

65

26(40.0%)

39(60.0%)

OS, 53 versus 47 months, P = 0.901; and median DFS, 36
versus 34 months, P = 0.706).

Discussion
Our study is very unique compared to other reports since
we selected the ESCC esophagectomy samples without
neoadjuvant chemoradiotherapy, which excluded the possible treatment effect on PD-L1 expression. In the current

study, we found that 29.9% of T2-T4a ESCC cases were
positive for PD-L1 in tumor cells and 40.2% positive in
tumor-infiltrating immune cells. In addition, PD-L1 expression in ESCC tumor cells was associated with various
clinicopathological parameters including age, degree of
differentiation, stage, metastasis and DFS.
PD-L1 positive expression in ESCC tumor cells has been
reported in several studies from 18.9 to 45% [10–14]. Our

Table 4 The relationship between tumor cells and tumor-infiltrating immune cells for PD-L1 expression
Variables

Overall

Tumor cells PD-L1(−)

Tumor cells PD-L1(+)

r
0.160

Tumor-infiltrating immune cells PD-L1(−)

226

172(76.1%)

54(23.9%)

Tumor-infiltrating immune cells PD-L1(+)

152

93(61.2%)

59(38.8%)

P value
0.002
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Fig. 2 PD-L1 expression in esophageal squamous cell carcinoma (ESCC) tumor cells and tumor-infiltrating immune cells. a PD-L1 positive expression in
tumor cells and tumor-infiltrating immune cells. Original magnification, 400×, (Black arrow shows the tumor-infiltrating immune cells). b PD-L1 negative
expression in tumor cells and tumor-infiltrating immune cells. Original magnification, 400×, (Black arrow shows the tumor-infiltrating immune cells)

current study showed that 29.9% of ESCC cases were
positive for PD-L1 in tumor cells. These differences
might be due to several factors including antibodies,
cut-off points, neoadjuvant therapy or IHC methods.
For example, Chen and his colleagues found that 45%
of ESCC tissues showed positive PD-L1 immunoreactivity [10]. However, their study included neoadjuvant
chemoradiotherapy patients. Based on the data from
another study, Lim et al. found PD-L1 (5H1) expression increased in ESCC patients who received neoadjuvant therapy [11]. Our present study excluded the
patients who had accepted neoadjuvant chemoradiotherapy. In addition, Ito S et al. found that 18.9% of
ESCC tissues had positive PD-L1 (LS-B480) expression [13]. However, their study used the scoring for
PD-L1 expression based on adding both the proportion score and the intensity score with cut-off as ≥7,

which is different from the current PD-L1 evaluation
guideline from clinical application. In our study, we
designated PD-L1 positive when ≥1% of the tumor
cells or immune cells were positive for PD-L1.
The association between PD-L1 expression and clinicopathological features was reported in several studies.
The lymph node metastasis and tumor stages were
found to associate with PD-L1 expression in most
studies [10–13]. In our study, we had similar finding.
In addition, we also showed that PD-L1 expression
was associated with age and tumor differentiation.
We found the PD-L1 expression were significantly
higher in old patients (35%) than young patients
(25%). We also found that poor differentiation ESCC
had higher PD-L1 expression (42%) compared to well
(25%) and moderate (27%) differentiation groups. We
did not find that tumor location was associated with

Fig. 3 Kaplan-Meier curves of disease-free survival (DFS) and overall survival (OS) in esophageal squamous cell carcinoma (ESCC) based upon
PD-L1 expression in tumor cells. a Patients with PD-L1 expression had significantly shorter DFS than those without PD-L1 expression (median DFS
time: 18 verse 41 months, P = 0.008). b There was no statistically significant difference in OS between the patients with positive and negative
PD-L1 staining (median OS time: 36 verse 60 months, P = 0.140)
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Table 5 Univariate COX analysis to determine factors associated with patient survival for PD-L1 expression in tumor cells
Variables

Overall survival
Hazard ratios

Disease-free survival
95%CI

P value

0.929-1.653

0.144

Hazard ratios

95%CI

P value

1.095-1.883

0.009

0.932-1.557

0.154

0.684-1.297

0.714

PD-L1
Negative

1

Positive

1.240

1
1.436

Age
<60 years

1

≥60 years

1.303

1
0.995-1.705

0.054

1.205

0.737-1.448

0.849

0.942

Gender
Female

1

Male

1.033

1

Tumor differentiation
Well

1

1

Moderate

1.383

0.954-2.005

0.087

1.458

1.025-2.074

0.036

Poor

2.150

1.435-3.222

<0.001

2.180

1.478-3.216

<0.001

Basaloid

1.774

0.828-3.804

0.141

2.162

1.052-4.444

0.036

Location
Upper thoracic

1

Middle thoracic

0.872

0.602-1.262

0.468

1
0.960

0.669-1.379

0.826

Lower thoracic

0.798

0.529-1.204

0.282

0.900

0.604-1.341

0.604

0.984-1.847

0.063

1.019-1.859

0.037

PT status
pT2

1

pT3-4a

1.348

1
1.377

PN status
pN0

1

1

pN1

2.175

1.575-3.002

<0.001

2.277

1.681-3.084

<0.001

pN2

3.703

2.542-5.394

<0.001

3.291

2.284-4.744

<0.001

pN3

9.401

5.707-15.486

<0.001

8.029

4.875-13.225

<0.001

1.415-2.427

<0.001

1.714

1.326-2.218

<0.001

1.267-2.138

<0.001

2.716-4.873

<0.001

Vascular invasion
No

1

Yes

1.853

1

Perineural invasion
No

1

Yes

1.707

1
1.297-2.245

<0.001

1.645

1.868-3.435

<0.001

3.638

Metachronous hematogenous metastasis
No

1

Yes

2.533

1

PD-L1 expression, which was reported by Chen’s
study [10].
The association of PD-L1 expression with ESCC patient’s prognosis was controversial. Most of studies
found that PD-L1 expression was significantly related
with worse overall survival or disease free survival
[10, 11, 13–17, 20, 21]. However, a few studies reported that PD-L1 positivity was associated with a favorable prognosis [12, 22, 23]. In our study, we found

that PD-L1 expression in tumor cells was significantly
correlated with DFS (41 months vs 18 months, PD-L1
negative vs positive) with univariate Cox analysis, but
multivariate Cox analysis failed to show PD-L1 as an
independent prognostic factor. In addition, we found
that the median OS was 60 months in PD-L1 negative
patients and 36 months in PD-L1 positive patients, respectively. However, it was not statistically significant
(P = 0.140). Based on current data, PD-L1 expression
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Table 6 Multivariate Cox analysis to determine independent factors associated with patient survival for PD-L1 expression in tumor cells
Variables

Overall survival
Hazard ratios

Disease-free survival
95%CI

P value

0.648-1.200

0.423

Hazard ratios

95%CI

P value

0.782-1.401

0.758

1.109-1.875

0.006

0.834-1.703

0.334

PD-L1
Negative

1

Positive

0.882

1
1.047

Age
<60 years

1

≥60 years

1.623

1
1.223-2.152

0.001

0.736-1.586

0.691

1.442

Tumor differentiation
Well

1

Moderate

1.081

1
1.192

Poor

1.369

0.890-2.107

0.153

1.533

1.030-2.280

0.035

Basaloid

1.109

0.507-2.425

0.796

1.128

0.538-2.367

0.750

0.945-1.776

0.108

1.617-2.977

<0.001

PT status
pT2

1

pT3-4a

1.119

1
0.800-1.565

0.512

1.485-2.841

<0.001

1.295

PN status
pN0

1

pN1

2.054

1
2.194

pN2

3.316

2.242-4.906

<0.001

3.188

2.201-4.616

<0.001

pN3

8.016

4.726-13.749

<0.001

7.865

4.682-13.210

<0.001

0.831-1.464

0.497

1.012-1.736

0.041

2.499-4.517

<0.001

Vascular invasion
No

1

Yes

1.291

1
0.970-1.718

0.080

0.999-1.764

0.051

1.103

Perineural invasion
No

1

Yes

1.328

1
1.325

Metachronous hematogenous metastasis
No

1

Yes

2.073

1
1.520-2.827

might be related with poorer prognosis, which might
be caused by the association of PD-L1 expression
with elder patients, lymph node metastasis, poor differentiation and later stages.
Furthermore, we found the PD-L1 expression in ESCC
tumor-infiltrating immune cells was 40.2% (152/378).
PD-L1 expression in tumor-infiltrating immune cells
was significantly associated with N stage and PD-L1 expression in tumor cells. We analyzed the prognostic
relevance of PD-L1 expression in tumor-infiltrating immune cells and showed that the median OS and DFS
were longer in patients with PD-L1 expression in
tumor-infiltrating immune cells, which was consistent
with recent study by Zhang et al. [18]. This might be an
indicator of a host immune response to tumor cells that
led to improve survival.

<0.001

3.359

In addition, we also evaluated PD-L1 expression if the
cut-off point was 10% or 50%, based on the
percent-positive tumor cells by IHC, the PD-L1 positive
expression in tumor cells was 16.4 and 7.4%, respectively. The positive expression of PD-L1 in ESCC tumor
cells was associated with tumor differentiation, T stage
and shorter DFS (Hazard ratio [HR] = 1.488, P = 0.017)
when the cut-off point was 10%, but not correlated with
OS (Hazard ratio [HR] = 1.255, P = 0.210), just as the result of the cut-off point was 1% (OS, Hazard ratio [HR]
= 1.240, P = 0.144; and DFS, Hazard ratio [HR] = 1.436,
P = 0.009). If the cut-off point was 50%, PD-L1 expression was just associated with age, but no significant association was found between PD-L1 expression and the
prognosis (OS, Hazard ratio [HR] = 1.304, P = 0.293; and
DFS, Hazard ratio [HR] = 1.344, P = 0.218).
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PD-L1 positive expression in our data was relative
lower than the results from one meta-analysis [24]. The
lower PD-L1 expression in our TMA data might be
caused by tumor heterogeneity [25]. In order to reduce
the discordance of PD-L1 expression, TMAs in our
study were constructed from three cores of tumor tissue
and three cores of normal epithelium from each case.
One study showed that TMAs correlated moderately
well with that in the corresponding whole slide surgical
specimens [26].
To our knowledge, this is the first study that systematically analyzed the prognostic relevance of PD-L1 expression in tumor cells and tumor-infiltrating immune
cells in advanced ESCC patients who received radical
esophagectomy without neoadjuvant chemoradiotherapy.
ESCC patients with T2 or more advanced stages had
worse prognosis than T1 stage and were more likely to
be benefit from immunotherapy. The T1 stage ESCC patients had good prognosis, most of whom needed no adjuvant therapy after surgery, so we didn’t include the T1
stage ESCC patients in our study. However, our study
had some limitations. We examined PD-L1 expression
mainly in only sampled a small esophageal volume to
examine the prognostic value, which might result in
undersampling of esophageal cancer tissue and it was a
retrospective analysis of a population with different
stages from a single institution, the issue should be best
answered in context of a prospective study in a more patient population.

Conclusions
In conclusion, PD-L1 expression in ESCC is not only an indicator for immunotherapy, but also is a potential prognostic marker for untreated ESCC patients. PD-L1 expression
in both tumor cells and tumor-infiltrating immune cells is
significantly associated multiple clinicopathological features
including age, differentiation, stage and metastasis.
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